Menu
Search
|

Menu

Close
X

Egalet Corp EGLT.OQ (NASDAQ Stock Exchange Global Market)

0.72 USD
+0.01 (+0.85%)
As of Feb 24
chart
Previous Close 0.71
Open 0.71
Volume 69,913
3m Avg Volume 261,129
Today’s High 0.72
Today’s Low 0.68
52 Week High 5.58
52 Week Low 0.68
Shares Outstanding (mil) 43.05
Market Capitalization (mil) 53.81
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
18
FY16
17
FY15
23
EPS (USD)
FY17
-2.522
FY16
-3.696
FY15
-3.132
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
2.39
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
-104.98
14.43
Return on Equity (TTM)
vs sector
-1,714.46
16.13

EXECUTIVE LEADERSHIP

Timothy Walbert
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Robert Radie
President, Chief Executive Officer, Director, Since 2012
Salary: $475,000.00
Bonus: $215,000.00
Stanley Musial
Chief Financial Officer, Executive Vice President, Secretary, Since 2015
Salary: $294,500.00
Bonus: $76,500.00
Mark Strobeck
Chief Operating Officer, Executive Vice President, Since 2015
Salary: $328,000.00
Bonus: $153,200.00
Paul Varki
Senior Vice President, General Counsel, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

600 Lee Rd Ste 100
WAYNE   PA   19087-5624

Phone: +1610.8334200

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company's product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company's product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company's product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company's product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.

SPONSORED STORIES